Illumina News and Research

RSS

Researchers sequence entire transcriptome of mouse neural retina

The population of Eric Morrow's seminar "Neurogenetics and Disease" comprises mainly undergraduates who were skipping down the halls of their elementary schools when the first drafts of human genome sequences were published. When Morrow, assistant professor of biology, recently asked the class how to find the mutation behind a disease, a hand shot up in the back of the class to signal the answer: "Sequence the patient's genome."

8 Dec 2011

Study presents high-resolution genome-wide p53-binding map for normal human cells

Scientists investigating the interactions, or binding patterns, of a major tumor-suppressor protein known as p53 with the entire genome in normal human cells have turned up key differences from those observed in cancer cells. The distinct binding patterns reflect differences in the chromatin (the way DNA is packed with proteins), which may be important for understanding the function of the tumor suppressor protein in cancer cells.

1 Dec 2011

Ambry Genetics deploys EMC Isilon scale-out NAS for gene sequencing

EMC Corporation today announced that Ambry Genetics, a leading commercial provider of clinical diagnostic and genomic services, has deployed EMC Isilon scale-out NAS to power its advanced gene sequencing operations, enabling Ambry to advance a range of scientific pursuits while easily managing 100 percent data growth annually.

30 Nov 2011

Scientists identify 16M SNPs that associate with risk of gout, serum uric acid levels

Scientists at deCODE Genetics and academic collaborators from Iceland, Norway, Denmark, the Netherlands and the USA report the discovery of low frequency variants in the human genome that associate with risk of gout, a common inflammatory arthritis, and serum uric acid levels.

10 Oct 2011

Illumina, UNTHSC enter next-generation sequencing collaboration in forensic DNA analysis

Illumina, Inc. today announced it has entered into a wide-ranging collaborative research agreement with the Institute of Applied Genetics and the Department of Forensic and Investigative Genetics at the University of North Texas Health Science Center (UNTHSC). Illumina and UNTHSC will collaborate on several visionary projects in forensics using Illumina's next-generation sequencing technologies.

From Illumina, Inc. 4 Oct 2011

Scientists discover 16 million SNPs that associate with increased risk of ovarian cancer

Scientists at deCODE Genetics and academic collaborators from Iceland, The Netherlands, Spain and Finland today report the discovery of variants in the human genome that associate with increased risk of invasive ovarian cancer, one of the deadliest forms of cancer in women.

3 Oct 2011

ITFoM FET Flagship pilot project to be presented at European Parliament seminar

On 20 September 2011, the Information Technology: Future of Medicine (ITFoM) FET Flagship pilot project will be presented at a seminar in the European Parliament.

8 Sep 2011

Federal Circuit affirms dismissal of Illumina's patent infringement lawsuits against Affymetrix

Affymetrix, Inc. today announced that the U. S. Court of Appeals for the Federal Circuit has affirmed the dismissal of the patent infringement lawsuits brought against the Company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020.

From Illumina, Inc. 22 Aug 2011

Illumina and University of Oxford collaborate to sequence whole genomes

Illumina, Inc. today announced it will collaborate with the University of Oxford to sequence the whole genomes of 500 individuals afflicted with a range of life-threatening diseases that pose major challenges in diagnosis, treatment, and care. Illumina HiSeq™ 2000 systems will be used to generate sequence data for the 500 genomes.

From Illumina, Inc. 3 Aug 2011

Illumina board authorizes new $100 million share repurchase program

Illumina today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.

From Illumina, Inc. 3 Aug 2011

Illumina begins to ship HumanOmni5-Quad DNA Analysis BeadChip

Illumina, Inc. today announced that it has begun shipping the HumanOmni5-Quad DNA Analysis BeadChip (Omni5), the new flagship array of the Omni family of microarrays.

From Illumina, Inc. 25 Jul 2011

Illumina announces availability of new TruSeq Custom Enrichment kits

Illumina, Inc. today announced availability of its new TruSeq Custom Enrichment kits which enable researchers to economically design and target genomic regions of interest ranging from 700 kilobases (Kb) to 15 megabases (Mb) of cumulative DNA.

From Illumina, Inc. 13 Jul 2011

Illumina, Sequenom sign three-year supply agreement

Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced it has signed a three-year supply agreement with Illumina, Inc., a leading developer and manufacturer of life sciences tools for the large-scale analysis of genetic variation and function.

From Illumina, Inc. 11 Jul 2011

Nature journal publishes landmark genetic study of ovarian cancer

A University of Houston researcher is an author on a landmark multi-institutional genetic study of the most aggressive and common form of ovarian cancer that is published in the current issue of the scientific journal Nature.

11 Jul 2011

Gene Codes releases Sequencher 5.0

Gene Codes Corporation announces the release of Sequencher 5.0. It incorporates new DNA sequence data alignment algorithms with SNP and methylation analysis for next-generation DNA sequence data. Performance for assembly and alignment of sequences and contigs is hundreds of times faster.

28 Jun 2011

BGI releases third version of assembled E. coli O104 genome

Scientists worldwide have been working on the publicly available genomic sequences of the deadly E. coli O104 strain, which is causing the current health crisis in Germany and now spreading throughout Europe. To continue to speed the ongoing international efforts of researchers to assess and halt this growing epidemic, BGI and their collaborators at the University Medical Centre Hamburg-Eppendorf have now released their third version of the assembled genome, which includes new data from this E. coli O104.

8 Jun 2011

GenoLogics enhances LIMS software for next-generation genomics labs

GenoLogics, a leading provider of laboratory information management system (LIMS) software for next-generation genomics labs, today announced a detailed product roadmap for its eponymous LIMS, designed to provide the scalability, adaptability and usability features necessary for mainstream adoption of the most advanced sequencing technologies while supporting existing genotyping platforms.

11 May 2011

Illumina announces price reduction in whole human genome sequencing projects

Illumina, Inc. today announced that it is significantly reducing the price for sequencing whole human genomes through the Illumina Genome Network.

From Illumina, Inc. 9 May 2011

Oxford Nanopore raises $41 million via private placement of ordinary shares

Oxford Nanopore Technologies Ltd., the UK-based developers of nanopore technology for the direct, electronic analysis of single molecules, today announced that it has raised £25 million in new funding via a private placement of ordinary shares in the Company.

From Oxford Nanopore Technologies 26 Apr 2011

Trial of non-invasive prenatal test to determine Down syndrome successful

At the moment, the only reliable way of diagnosing chromosomal irregularities during pregnancy is to use invasive prenatal methods. This causes miscarriage in about one per cent of these risky surgical procedures.

14 Apr 2011